Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN)
Recruitment status was: Recruiting
This study will evaluate the safety of candidate malaria vaccine MSP3 in children aged 12-24 months in Tanzania in a highland area with low malaria transmission.
Written informed consent will be sought from all guardians/parents of potentially participating children. Eligible children will be randomly allocated to receive either the the study vaccine (MSP3 for a total of 30 children)) or the control vaccine (hepatitis B for a total of 15 children). The vaccines will be given in 3 immunizations one month apart to all the study children and neither the clinical investigators nor the children's parents will be aware of which vaccine has been administered during the initial four months of the study. The study is designed to begin with a lower dose of the MSP3 vaccine (15µg of MSP3 for 15 children) and then followed by the higher dose(30µg MSP3 for 15 children). Following each immunization, children will be evaluated for a seven day solicited symptoms. Unsolicited symptoms will also be collected throughout the study duration.
The study will be overseen by an international safety monitoring committee who will follow safety matters closely as the trial progresses. The study will also be approved by the Tanzania National ethics Committee, The Tanzania Food and Drugs Authority, and the London school of hygiene and tropical medicine ethics committee. The study is planned to last 13 months for each participant.
|Malaria||Biological: MSP 3 Long Synthetic Peptide Biological: MSP3 vaccine Biological: Hepatitis B vaccine Biological: MSP3 candidate vaccine Biological: Hepatitis B control vaccine||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine|
- Safety of MSP3 by assessing the reactogenicity [ Time Frame: Solicited and unsolicited adverse events (immediate reactogenicity within 60 minutes of each vaccination; 7-day assessment, and 28 days ]
- The humoral response to vaccine antigens will be assessed by measuring by ELISA [ Time Frame: ELISA on D0, D28, D56, D84, D168 and D365 ]
|Study Start Date:||October 2007|
|Estimated Study Completion Date:||August 2008|
15 microgramme candidate vaccine
Biological: MSP3 vaccine
Lyophilized vaccine adjuvanted in Aluminium hydroxide
Active Comparator: 2
Hepatitis B vaccine
Biological: Hepatitis B vaccine
Hepatitis B vaccine adjuvanted in Aluminium hydroxide
30 microgramme MSP3 candidate malaria vaccine
Biological: MSP 3 Long Synthetic Peptide
Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxideBiological: MSP3 candidate vaccine
Lyophilized MSP3 adjuvanted in Aluminium hydroxide
Active Comparator: 4
Hepatitis B control vaccine
Biological: Hepatitis B control vaccine
Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
The study is a double blind (observer blind, participant blind), randomized, controlled, dose escalation, Age deescalation, phase Ib study. It will include two parallel groups as follows:
- Group 1: 23 subjects (15 subjects receiving MSP3-LSP vaccine 15 µg and 8 subjects receiving Hepatitis B vaccine).
- Group 2: 22 subjects (15 subjects receiving MSP3-LSP vaccine 30 µg and 7 subjects receiving Hepatitis B vaccine).
The Immunization schedule will be 0, 1, and 2 months for all cohorts and provisionally as following for each group:
- Study days 0, 28 and 56 for group 1
- Study days 14, 42, 70 for group 2 Vaccinations of groups 1 and 2 will be staggered: immunization in group 2 will start 2 weeks after group 1. This interval may be extended if deemed necessary in case of serious adverse events or other safety concerns. Randomization will be done for each group at the time of first vaccinations and only the study pharmacist will be aware of which vaccine is allocated to a particular study ID number. The pharmacist will have no other role and will be sworn to confidentiality.
The study vaccine will be administered through the subcutaneous injection into right or left deltoid (alternately). Each child will be observed for at least 60 minutes after vaccination to evaluate and treat any acute adverse events.
This will be followed by a Seven (7) day follow-up period for solicited adverse events (day of vaccination plus 6 subsequent days; twenty eight (28) day follow-up period for unsolicited adverse events (Vaccination day plus 27 subsequent days). The follow-up of serious adverse events (SAE's) for 12 months after the first dose of study vaccine (9 months after dose 3). Biological safety will be evaluated through regular physical examinations, blood sampling for routine clinical chemistry, and hematology). At the end of the follow-up period for unsolicited AEs (i.e., one month after the third dose), children will be followed by field workers at home at monthly intervals to record SAEs. There are 10 clinic visits planned, however, participants will be advised to report to the clinic any time they feel unwell.
Data collection will be through participant record files from which transcription on to conventional Case Report Forms will be done. All the date on the CRFs will be verified by the clinical Monitor. The database will be locked after study day 84 to allow for an interim analysis to review safety and immunogenicity thus collected.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469651
|Contact: Roma Chilengi, MD, MSc||+255 22 email@example.com|
|Contact: Abdalla Noor, MD, MPH||+255 22 firstname.lastname@example.org|
|Korogwe, Tanga, Tanzania|
|Contact: John P Lusingu, MD, PhD +255 787 679515 email@example.com|
|Principal Investigator: John P Lusingu, MD, PhD|
|Sub-Investigator: Samuel Gesase, MD, MSc|
|Study Director:||Martha M Lemnge, MS, PhD||National Institute For Medical Research in Tanzania|
|Principal Investigator:||John P Lusingu, MD, PhD||National Institute for Medical Research in Tanzania|